Despite extensive research, the etiopathogenesis of primary Sjögren's syndrome is not well understood. In this article, the hypothesis that activation of the type I interferon system contributes to the disease process is outlined and potential new therapeutic targets from this system for Sjögren's syndrome are discussed.
- Gunnel Nordmark
- Gunnar V Alm
- Lars Rönnblom